Solara Active Pharma Sciences Ltd. · NSE:SOLARA

Solara Active Pharma Sciences — Q1 FY2020 Earnings Presentation

20 slides from Solara Active Pharma Sciences's earnings presentation, Aug 13, 2019

  1. Slide 1: Outcome of Board Meeting cover letter

    Communication Address· SOLARA Active Pharma Sciences Solara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy. Chennai - 600 032. India Tel : +91 44 43446700, 22207500 Fax : +91 44 22350278 August 13, 2019 The BSE Limited The National Stock Exchange of India

  2. Slide 2: Independent Auditor's Review Report (Consolidated)

    7 Chartered Accountants Deloitte Prange rode Tower Level 19 - 46, Palace Road, High Grounds Haskins & Sells LLP Bengaluru 36001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS. TO THE BOARD OF DIRECTORS OF SOLARA

  3. Slide 3: Independent Auditor's Review Report (continued)

    Deloitte Haskins & Sells LLP 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the

  4. Slide 4: Statement of Consolidated Unaudited Financial Results

    SOLARA ACTIVE PHARMA SCIENCES LIMITED: SOLARA fg Ofte No 201 Deva eco 17 Ves Ne! Mumba 0 708 ou Cop. Oe: No, Sardar Ptel Rood, Gay Chenal = 40082 STATEMENT OF CONSOLIDATED UNAUDITED FNANCIAL RESUS FOR HE QUARTER ENDED ANE 30,209 ’ (tenLakie ecopt pr sare dota [si No. Particulars Corresponding 3 i re

  5. Slide 5: Consolidated Financial Results Notes

    ‘SOLARA ACTIVE PHARMA SCIENCES LIMITED Regd. Office: Ne. 201 Devawrata, Sector 17, Vashi, Navi Mumbai 400 703. Corp, Office: No 28, Sardar Patel Road, Guindy, Chennal - 600 082 STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019 The above results were reviewed b

  6. Slide 6: Independent Auditor's Review Report (Standalone)

    a Chartered Accountants le Ol e Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Haskins & Sells LLP ee nae Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF SOLARA ACTIVE PHARMA SCIENCES LI

  7. Slide 7: Statement of Standalone Unaudited Financial Results

    ‘SOLARA ACTIVE PHARMA SCIENCES LIMITED SOLARA Regd, Office: No, 201 Devavrata, Sector 17, Vash, Navi Mumbal 400 703. a ee Corp. Office: No 28, Sardar Patel Road, Guindy, Chennal- 600 032 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2019 (Rs. In Lakhs except per s

  8. Slide 8: Standalone Financial Results Notes

    SOLARA ACTIVE PHARMA SCIENCES LIMITED SOLARA Regd. Office: No, 201 Devavrata, Sector 17, Vashi, Navi Mumbal 400 703. cies Corp. Olfice: No 28, Sardar Patel Road, Guindy, Chennal - 600 032 Favre Paes Soc ‘STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FORTHE QUARTER ENDED JUNE 0, 2019 Notes Plac

  9. Slide 9: Press Release: Solara announces Q1FY20 Financial Results

    PRESS RELEASE Q1FY20 WWW.SOLARA.CO.IN | BSE:541540 NSE: SOLARA BLOOMBERG:SOLARA:IN | SECTOR:PHARMACEUTICALS Solara announces Q1FY20 Financial Results » Revenues at ₹3,345 Mn up by 10% YoY with 42% YoY growth in EBITDA to ₹663 Mn » 3x growth in PAT to ₹265 Mn in Q1FY20 » Reported highest ever EPS in

  10. Slide 10: Business Updates, EBITDA Reconciliation, Earnings Conference Call

    PRESS RELEASE Business Updates » The regulated markets grew 6% YoY and represents 75% of the total revenue. » Commercialised one new product in the quarter. New products as percent of total revenues now at 7% » Cuddalore API facility cleared FDA inspection with zero 483s » Accreditation of Foreign M

  11. Slide 11: Growth Through Efficiency Q1'20

    GROWTH THROUGH EFFICIENCY Q1’20 Earnings Update August 13 , 2019

  12. Slide 12: Agenda

    PERFORMANCE HIGHLIGHTS BUSINESS UPDATES Agenda CORPORATE UPDATES FUTURE OUTLOOK

  13. Slide 13: Q1'20 delivers a stellar financial performance

    Q1’20 delivers a stellar financial performance REVENUE EBITDA PAT (₹ in million) (₹ in million) (₹ in million) 3,345 3,033 265 663 We are pleased to start the financial year with a satisfying 465 performance. While we reported a 10% YoY growth in 92 revenues, we had a significant 42% growth in EBITD

  14. Slide 14: Margin expansion continues despite increased R&D activity

    Margin expansion continues despite increased R&D activity YEAR ON YEAR MOVEMENT QUARTERLY PERFORMANCE UPDATES  Operating EBITDA improvement led by changed product mix and Particulars Q1 FY20 Q1 FY19 Change favorable outcomes from cost improvement program Revenue 3,345 3,033 10%  19% YoY increase i

  15. Slide 15: Significant improvement in profitability over last 5 quarters

    Significant improvement in profitability over last 5 quarters REPORTED EBITDA NET PROFIT AFTER TAX EARNINGS PER SHARE (₹ in million) (₹ in million) (₹/share) 800 0.5 701 700 656 663 0.45 0.4 10.2 10.3 600 262 265 0.35 9.0 494 221 500 465 0.3 400 0.25 18.2% 19.8% 17.9% 300 15.3% 0.2 14.4% 92 96 3.9 0

  16. Slide 16: Right sized balance sheet with improvements in key ratios

    Right sized balance sheet with improvements in key ratios SOURCES OF FUND KEY UPDATES Particulars Mar’18 Mar’19 Jun’19  Improvements in financial ratios led by a right sized balance Shareholders' funds 7,640 9,559 9,837 sheet position Less: Goodwill -3,634 -3,587 -3,587 Net worth 4,006 5,972 6,250

  17. Slide 17: Future Outlook

    Future Outlook

  18. Slide 18: FY20 growth led through efficiencies

    FY20 growth led through efficiencies FOCUSED R&D STRATEGIES • Focus on developing IP to create entry barrier for competition and build strong intrinsic value • Market specific launches with products having limited competition • Filing capability of 10-12 DMF/annum EFFICIENCIES IN OPERATIONS • Proact

  19. Slide 19: Well on our path to become a disruptive player in API industry

    Well on our path to become a disruptive player in API industry BUSINESS CONTINUITY WORLD WIDE PRESENCE CUSTOMER ADVOCACY A steadily expanding portfolio of new An entrenched footprint in key regulated A unilateral focus on customer delight products and new customers to access markets as well as oppor

  20. Slide 20: Thank you

    Thank you REGISTERED OFFICE CORPORATE OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703. 3rd & 4th Floor, Batra Centre, No.28, Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Sardar Patel Road, Guindy, Chennai - 600 032 Email: investors@solara.co.in Tel.: +91 44 4344 6700 / 2220 7500 We

Solara Active Pharma Sciences — Q1 FY2020 Earnings Presentation on 6ix